TY - JOUR
T1 - Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions
T2 - Results of the cross-sectional ASAS-COMOSPA study
AU - Kishimoto, Mitsumasa
AU - Ono, Keisuke
AU - Fukui, Sho
AU - Kawaai, Satoshi
AU - Deshpande, Gautam A.
AU - Yoshida, Kazuki
AU - Ichikawa, Naomi
AU - Kaneko, Yuko
AU - Kawasaki, Taku
AU - Matsui, Kazuo
AU - Morita, Mitsuhro
AU - Tada, Kurisu
AU - Takizawa, Naoho
AU - Tamura, Naoto
AU - Taniguchi, Atsuo
AU - Taniguchi, Yoshinori
AU - Tsuji, Shigeyoshi
AU - Okada, Masato
AU - Kobayashi, Shigeto
AU - Komagata, Yoshinori
AU - López-Medina, Clementina
AU - Molto, Anna
AU - Van Der Heijde, Desirée
AU - Dougados, Maxime
AU - Tomita, Tetsuya
AU - Kaname, Shinya
N1 - Funding Information:
Competing interests MK: Consulting fees and/or honoraria from AbbVie, Amgen-Astellas BioPharma, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, Teijin Pharma and UCB Pharma. KY: Consulting fees from OM1. Funding from Corrona. KY was additionally supported by the Rheumatology Research Foundation K Bridge Award, Brigham and Women's Hospital Department of Medicine Fellowship Award, and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Career Development Award (K23AR076453). YK: Grants or speaking fees from from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. NT: Speaker fees and/or consulting fees from AbbVie, Astellas, Bristol-Myers Squibb, Eisai, Eli Lilly, Janssen, Kyowa Kirin, Mitsubishi-Tanabe and Novartis. SK: Personal fees from Kyowa Kirin, Novartis Pharma K.K., Eli Lilly Japan K.K., Chugai Pharma, Asahi Kasei Pharma, Gilead Sciences and Janssen Pharma K.K. outside the submitted work. CL-M: Speaking fees from Janssen, Abbvie and UCB. AM has received research grants from Abbvie, Bristol-Myers Squibb, Gilead, MSD, Pfizer, Jansen, UCB. DvdH: Consulting fees AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma. Director of Imaging Rheumatology bv. TT: Consultancy and speaker fees from AbbVie, Astellas, Bristol-Myers Squibb, Eisai, Eli Lilly and Company, Janssen, Kyowa Kirin, Mitsubishi-Tanabe, Novartis and Pfizer. All other authors have declared no conflicts of interest.
Funding Information:
Funding This study was conducted under the umbrella of the International Society for Spondyloarthritis Assessment (ASAS) and COMOSPA study was supported by unrestricted grants from Pfizer, AbbVie and UCB.
Funding Information:
17Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands 18Department of Orthopaedic Biomaterial Science, Osaka University School of Medicine Graduate School of Medicine, Suita, Osaka, Japan Acknowledgements Part of this study was presented in the EULAR2021 (#POS0975). This study was conducted under the umbrella of the International Society for Spondyloarthritis Assessment (ASAS) and COMOSPA study was supported by unrestricted grants from Pfizer, AbbVie and UCB.
Publisher Copyright:
© Author(s) (or their employer(s)) 2021.
PY - 2021/9/16
Y1 - 2021/9/16
N2 - Objectives To delineate characteristics of non-radiographic axial spondyloarthritis (nr-axSpA) in Asia versus non-Asian regions, and compare radiographic axSpA (r-axSpA) with nr-axSpA within Asia. Methods Data were collected from the Assessment of SpondyloArthritis international Society-COMOrbidities in SPondyloArthritis database. Categorising patients by region, we compared clinical characteristics between nr-axSpA from Asia vs elsewhere (Europe, the Americas and Africa). Within Asians, we additionally compared patient characteristics of those with nr-axSpA versus r-axSpA. Results Among 3984 SpA cases, 1094 were from Asian countries. Of 780 axSpA patients in Asia, 112 (14.4%) had nr-axSpA, less than in non-Asian countries (486/1997, 24.3%). Nr-axSpA patients in Asia were predominantly male (75.9% vs 47.1%), younger at onset (22.8 vs 27.8 years) and diagnosis (27.2 vs 34.5 years), and experienced less diagnostic delay (1.9 vs 2.9 years) compared with nr-axSpA in non-Asian countries. Nr-axSpA in Asia exhibited higher human leucocyte antigens-B27 prevalence (90.6% vs 61.9%), fewer peripheral SpA features (53.6% vs 66.3%) and similar extra-articular and comorbid disease rates compared with those with nr-axSpA in non-Asian countries. Disease activity, functional impairment and MRI sacroiliitis were less in nr-axSpA in Asia, with higher rates of non-steroidal anti-inflammatory drug response and less methotrexate and biological disease-modifying antirheumatic drugs use. Within Asia, r-axSpA showed higher disease activity and structural damage compared with nr-axSpA, with no differences in other features. Conclusion Among axSpA, lower frequency of nr-axSpA was observed in Asia. Our results offer an opportunity to better understand clinical characteristics and optimise diagnostic strategies, such as ensuring access and availability of MRI resources for accurate diagnosis of nr-axSpA in Asia.
AB - Objectives To delineate characteristics of non-radiographic axial spondyloarthritis (nr-axSpA) in Asia versus non-Asian regions, and compare radiographic axSpA (r-axSpA) with nr-axSpA within Asia. Methods Data were collected from the Assessment of SpondyloArthritis international Society-COMOrbidities in SPondyloArthritis database. Categorising patients by region, we compared clinical characteristics between nr-axSpA from Asia vs elsewhere (Europe, the Americas and Africa). Within Asians, we additionally compared patient characteristics of those with nr-axSpA versus r-axSpA. Results Among 3984 SpA cases, 1094 were from Asian countries. Of 780 axSpA patients in Asia, 112 (14.4%) had nr-axSpA, less than in non-Asian countries (486/1997, 24.3%). Nr-axSpA patients in Asia were predominantly male (75.9% vs 47.1%), younger at onset (22.8 vs 27.8 years) and diagnosis (27.2 vs 34.5 years), and experienced less diagnostic delay (1.9 vs 2.9 years) compared with nr-axSpA in non-Asian countries. Nr-axSpA in Asia exhibited higher human leucocyte antigens-B27 prevalence (90.6% vs 61.9%), fewer peripheral SpA features (53.6% vs 66.3%) and similar extra-articular and comorbid disease rates compared with those with nr-axSpA in non-Asian countries. Disease activity, functional impairment and MRI sacroiliitis were less in nr-axSpA in Asia, with higher rates of non-steroidal anti-inflammatory drug response and less methotrexate and biological disease-modifying antirheumatic drugs use. Within Asia, r-axSpA showed higher disease activity and structural damage compared with nr-axSpA, with no differences in other features. Conclusion Among axSpA, lower frequency of nr-axSpA was observed in Asia. Our results offer an opportunity to better understand clinical characteristics and optimise diagnostic strategies, such as ensuring access and availability of MRI resources for accurate diagnosis of nr-axSpA in Asia.
KW - ankylosing
KW - arthritis
KW - epidemiology
KW - psoriatic
KW - spondylitis
UR - http://www.scopus.com/inward/record.url?scp=85115335476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115335476&partnerID=8YFLogxK
U2 - 10.1136/rmdopen-2021-001752
DO - 10.1136/rmdopen-2021-001752
M3 - Article
C2 - 34531305
AN - SCOPUS:85115335476
SN - 2056-5933
VL - 7
JO - RMD Open
JF - RMD Open
IS - 3
M1 - e001752
ER -
